What Is IGF-1 LR3? Dosage, Half-Life & How to Track It

What IGF-1 LR3 is and how it works

IGF-1 LR3 starts from human insulin-like growth factor 1 (IGF-1) — the hormone that mediates most of growth hormone’s downstream muscle- and tissue-building effects — and modifies it two ways: substituting an arginine for the glutamic acid at position 3 (the “R3”), and adding a 13-amino-acid extension to the front end (“Long”). Both changes exist for one purpose: reducing how tightly it binds to IGF binding proteins (IGFBPs), the proteins that normally mop up circulating IGF-1 within minutes.

Less binding to IGFBPs means more of an injected dose stays “free” and active in circulation, and the molecule also resists enzymatic breakdown better than native IGF-1 — the combined effect is something that acts longer and, milligram for milligram, more potently than your body’s own IGF-1. Functionally it behaves like growth hormone’s muscle-building arm: promoting protein synthesis and cell growth, and — because IGF-1 signaling overlaps with insulin signaling — a real blood-sugar-lowering effect at higher doses.

It’s a legitimate, well-characterized research compound (the binding-protein trick is textbook endocrinology), but the doses and schedules used outside research settings are entirely community-derived, and it’s not FDA-approved for any of those uses. The insulin-like hypoglycemia risk is real and is why practical doses stay conservative.

Typical dosing & reconstitution

IGF-1 LR3 ships lyophilized and is reconstituted with bacteriostatic water. Community protocols dose it low relative to most peptides — 20–50 mcg once daily subcutaneously, typically taken in the morning or post-workout alongside food, specifically to blunt the insulin-like drop in blood sugar it can cause.

Because the effective dose is so small, the recon math matters more than usual:

At 0.333 mg/mL, a 30 mcg dose is 9 units. This is one of the most diluted common peptide mixes precisely because the effective dose is so small — getting the concentration right matters more here than with almost anything else in this library.

Half-life & what it means for frequency

Native IGF-1 in the blood has a half-life measured in minutes because IGFBPs clear it almost immediately; IGF-1 LR3’s reduced binding-protein affinity extends that considerably — commonly cited in the range of many hours — though precise human PK numbers outside lab literature are sparse. That extension is what makes once-daily dosing workable instead of requiring near-continuous infusion.

Because the effect builds and fades over a day rather than minutes, timing relative to meals and training is more about managing the blood-sugar side effect than hitting a narrow pharmacokinetic window — food nearby is the practical guardrail people use.

What to track & common side effects

The standout side effect to watch is hypoglycemia — lightheadedness, shakiness, sweating — because IGF-1 LR3’s structure overlaps enough with insulin to activate some of the same receptors. Injection-site reactions round out the common list; this is a compound where more is not obviously better.

What’s worth tracking: dose and timing relative to food (useful context if a blood-sugar symptom ever needs sorting out), plus whatever body-composition or recovery outcome motivated starting it — since the effective doses are so small, a dosing log also doubles as a sanity check against accidentally drawing up more than intended.

Frequently asked questions